671 related articles for article (PubMed ID: 15242770)
21. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation.
Buck I; Morceau F; Cristofanon S; Heintz C; Chateauvieux S; Reuter S; Dicato M; Diederich M
Biochem Pharmacol; 2008 Nov; 76(10):1229-39. PubMed ID: 18805401
[TBL] [Abstract][Full Text] [Related]
22. The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells.
Kirschner KM; Hagen P; Hussels CS; Ballmaier M; Scholz H; Dame C
FASEB J; 2008 Aug; 22(8):2690-701. PubMed ID: 18424770
[TBL] [Abstract][Full Text] [Related]
23. EPO receptor-mediated ERK kinase and NF-kappaB activation in erythropoietin-promoted differentiation of astrocytes.
Lee SM; Nguyen TH; Park MH; Kim KS; Cho KJ; Moon DC; Kim HY; Yoon DY; Hong JT
Biochem Biophys Res Commun; 2004 Aug; 320(4):1087-95. PubMed ID: 15249201
[TBL] [Abstract][Full Text] [Related]
24. Role of tumour necrosis factor-alpha in dendritic cell-mediated primary mixed leucocyte reactions.
McKenzie JL; Calder VL; Starling GC; Hart DN
Bone Marrow Transplant; 1995 Feb; 15(2):163-71. PubMed ID: 7773205
[TBL] [Abstract][Full Text] [Related]
25. Trophoblastic cell lines generated from tumour necrosis factor receptor-deficient mice reveal specific functions for the two tumour necrosis factor receptors.
Rasmussen CA; Pace JL; Banerjee S; Phillips TA; Hunt JS
Placenta; 1999; 20(2-3):213-22. PubMed ID: 10195744
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
Grund EM; Kagan D; Tran CA; Zeitvogel A; Starzinski-Powitz A; Nataraja S; Palmer SS
Mol Pharmacol; 2008 May; 73(5):1394-404. PubMed ID: 18252806
[TBL] [Abstract][Full Text] [Related]
27. The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line Mo7e.
Liu RY; Fan C; Mitchell S; Chen Q; Wu J; Zuckerman KS
Cancer Res; 1998 May; 58(10):2217-23. PubMed ID: 9605769
[TBL] [Abstract][Full Text] [Related]
28. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
Hamadmad SN; Hohl RJ
Biochem Pharmacol; 2007 Aug; 74(4):590-600. PubMed ID: 17586475
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor-alpha up-regulates the expression of CCL2 and adhesion molecules of human proximal tubular epithelial cells through MAPK signaling pathways.
Ho AW; Wong CK; Lam CW
Immunobiology; 2008; 213(7):533-44. PubMed ID: 18656701
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.
Arcasoy MO; Karayal AF
Biochim Biophys Acta; 2005 Apr; 1740(1):17-28. PubMed ID: 15878737
[TBL] [Abstract][Full Text] [Related]
31. TNF-induced haptoglobin release from human neutrophils: pivotal role of the TNF p55 receptor.
Berkova N; Gilbert C; Goupil S; Yan J; Korobko V; Naccache PH
J Immunol; 1999 May; 162(10):6226-32. PubMed ID: 10229868
[TBL] [Abstract][Full Text] [Related]
32. Pluripotent stem cells constitutively expressing a normal erythropoietin receptor give rise to normal hematopoiesis in lethally irradiated recipient mice.
Lacout C; Dubart A; Vainchenker W; Duménil D
Exp Hematol; 1996 Jan; 24(1):18-25. PubMed ID: 8536787
[TBL] [Abstract][Full Text] [Related]
33. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO).
Johnson CS; Cook CA; Furmanski P
Exp Hematol; 1990 Feb; 18(2):109-13. PubMed ID: 2303102
[TBL] [Abstract][Full Text] [Related]
34. Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells.
Sakamoto H; Kitamura T; Yoshimura A
J Biol Chem; 2000 Nov; 275(46):35857-62. PubMed ID: 10960479
[TBL] [Abstract][Full Text] [Related]
35. Role of a truncated erythropoietin receptor for erythroid differentiation.
Nakamura Y; Tokumoto Y; Nakauchi H
Biochem Biophys Res Commun; 1996 Jan; 218(1):205-9. PubMed ID: 8573132
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin biology in cancer.
Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
[TBL] [Abstract][Full Text] [Related]
37. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha.
Bazzoni F; Regalia E
Cancer Res; 2001 Feb; 61(3):1050-7. PubMed ID: 11221832
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine residues of the erythropoietin receptor are dispensable for erythroid differentiation of human CD34+ progenitors.
Fichelson S; Chrétien S; Rokicka-Piotrowicz M; Bouhanik S; Gisselbrecht S; Mayeux P; Lacombe C
Biochem Biophys Res Commun; 1999 Mar; 256(3):685-91. PubMed ID: 10080960
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
[TBL] [Abstract][Full Text] [Related]
40. c-FLIP is involved in erythropoietin-mediated protection of erythroid-differentiated cells from TNF-alpha-induced apoptosis.
Vittori D; Vota D; Callero M; Chamorro ME; Nesse A
Cell Biol Int; 2010 May; 34(6):621-30. PubMed ID: 20218968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
